Croma-Pharma Expands U.S. Aesthetic Portfolio as FDA Approves Obagi saypha® ChIQ™ for Facial Volume Restoration
Croma-Pharma has reached another significant milestone in its global growth strategy with the U.S. Food and Drug Administration (FDA) approving Obagi saypha® ChIQ™, a hyaluronic acid-based injectable gel designed for facial aesthetic treatments. The approval strengthens the company’s presence in the United States and broadens the range of minimally invasive aesthetic solutions available to medical professionals and patients.
The latest authorization marks the second product from Croma-Pharma’s saypha® injectable portfolio to receive FDA approval. It follows the successful approval of Obagi saypha® MagIQ™ in September 2025, highlighting the company’s continued expansion in one of the world’s most competitive and influential medical aesthetics markets.
Expanding Treatment Options in Facial Aesthetics
Obagi saypha® ChIQ™ has been approved for cheek augmentation and the correction of midline facial asymmetry in adults aged 21 years and older. The injectable gel is formulated with hyaluronic acid, a naturally occurring substance found in the human body that plays an important role in maintaining skin hydration, elasticity, and volume.
As people age, the body’s natural production of hyaluronic acid gradually decreases. This reduction often results in volume loss, sagging skin, and changes in facial contours. Hyaluronic acid dermal fillers have become one of the most widely used non-surgical aesthetic treatments because they help restore lost facial volume while maintaining a natural appearance.
With the FDA’s approval of ChIQ™, healthcare providers in the United States will have another clinically validated option for restoring facial balance and improving cheek definition. The treatment is intended to provide enhanced facial contours while addressing asymmetry in the midface region, an area that plays a major role in overall facial harmony.
Strengthening Croma-Pharma’s Presence in the U.S.
The approval represents another major achievement for Croma-Pharma as it continues to strengthen its footprint in the United States. Although the company has established itself as a leading manufacturer of hyaluronic acid injectables in Europe and other international markets, gaining FDA approvals significantly expands its commercial opportunities in North America.
The United States remains one of the fastest-growing markets for aesthetic medicine, driven by increasing consumer demand for minimally invasive cosmetic procedures. Patients are increasingly seeking treatments that offer noticeable yet natural-looking results without the extended recovery times associated with surgical interventions.
By adding Obagi saypha® ChIQ™ to its U.S. portfolio, Croma-Pharma is well positioned to serve physicians, dermatologists, plastic surgeons, and aesthetic practitioners looking for advanced injectable solutions backed by rigorous regulatory standards.
Partnership with Obagi Medical
Obagi saypha® ChIQ™ was developed and manufactured by Croma-Pharma and will be marketed in the United States through Obagi Medical, a company operating under Waldencast. This strategic collaboration combines Croma-Pharma’s expertise in injectable product development with Obagi Medical’s strong presence in the professional skincare and aesthetic medicine market.
Obagi Medical has built a longstanding reputation among healthcare professionals for delivering science-based skincare products and physician-dispensed aesthetic solutions. Through this partnership, ChIQ™ is expected to reach a broad network of qualified providers across the country, ensuring that patients have access to the newly approved treatment.
The collaboration also supports both companies’ shared objective of delivering innovative aesthetic solutions that address evolving patient needs while maintaining high standards of safety and effectiveness.
Building on the Success of MagIQ™
The FDA approval of ChIQ™ follows the successful launch of Obagi saypha® MagIQ™, which became the first product from Croma’s saypha® portfolio to receive FDA clearance in September 2025.
The approval of two products within less than a year demonstrates Croma-Pharma’s commitment to expanding its injectable product portfolio in the United States. It also reflects the company’s broader strategy of bringing clinically proven aesthetic innovations to one of the world’s largest healthcare markets.
With both MagIQ™ and ChIQ™ now available, practitioners will have a broader selection of treatment options tailored to different facial indications and patient goals.
Rising Demand for Minimally Invasive Procedures
The medical aesthetics industry has experienced substantial growth over the past decade, with non-surgical cosmetic procedures becoming increasingly popular among consumers of different age groups. Hyaluronic acid dermal fillers have emerged as one of the leading treatment categories due to their versatility, predictable outcomes, and relatively short recovery periods.
Patients increasingly seek treatments that subtly enhance their appearance while preserving natural facial expressions. Procedures such as cheek augmentation and facial contouring are among the most requested aesthetic treatments because they can improve facial proportions and restore youthful volume without surgery.
The availability of another FDA-approved injectable provides physicians with greater flexibility in designing personalized treatment plans that address each patient’s unique facial anatomy and cosmetic objectives.
Importance of FDA Approval
Receiving FDA approval represents a significant achievement for any medical device or injectable product. The approval process requires manufacturers to provide extensive scientific and clinical evidence demonstrating the product’s safety and effectiveness for its intended use.
For healthcare providers, FDA approval offers additional confidence that the product has undergone comprehensive regulatory evaluation before entering the U.S. market. For patients, it provides reassurance that the treatment meets strict quality, manufacturing, and performance standards established by U.S. regulators.
The approval of Obagi saypha® ChIQ™ underscores Croma-Pharma’s commitment to maintaining high manufacturing standards and investing in clinical research to support its growing portfolio of aesthetic products.
Advancing Innovation in Aesthetic Medicine
Innovation continues to shape the future of aesthetic medicine, with manufacturers focusing on developing products that deliver natural-looking outcomes, long-lasting performance, and enhanced patient satisfaction.
Croma-Pharma has consistently invested in research, product development, and advanced manufacturing technologies to support innovation across its aesthetic portfolio. The company has earned international recognition for producing high-quality hyaluronic acid fillers and expanding access to minimally invasive treatment options.
The addition of ChIQ™ further reinforces the company’s position as an important contributor to advancements in facial aesthetic medicine.
Benefits for Healthcare Professionals
The approval of Obagi saypha® ChIQ™ gives physicians another clinically approved option for treating patients seeking improvements in facial volume and contour.
Healthcare professionals can incorporate the product into individualized treatment plans based on each patient’s facial structure, aesthetic goals, and treatment preferences. The availability of multiple products within the saypha® portfolio also allows practitioners greater flexibility when addressing different facial regions and cosmetic concerns.
As demand for personalized aesthetic treatments continues to grow, access to a broader portfolio of FDA-approved injectables can help providers deliver more tailored treatment experiences.
